EP2129383A1 — Treatment of anxiety disorders with minocycline
Assigned to Neuropharm Ltd · Expires 2009-12-09 · 16y expired
What this patent protects
The present invention relates to the use of a minocycline compound or a prodrug thereof; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for the treatment of an anxiety disorder in children or adolescents.
USPTO Abstract
The present invention relates to the use of a minocycline compound or a prodrug thereof; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for the treatment of an anxiety disorder in children or adolescents.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.